Expression of p27 and VHL in renal tumors

Applied Immunohistochemistry and Molecular Morphology

Volumn 10, Issue 4, 2002, Pages 344-350

  Osipov, Vladimir ^a   Keating, Jeffery T ^b   Faul, Peter N ^b   Loda, Massimo ^b,c   Datta, Milton W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cell cycle; Kidney tumor; p27; VHL

Indexed keywords

PROTEIN; PROTEIN P27; PROTEIN VON HIPPEL LANDAU; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADENOMA, OXYPHILIC; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LIGASES; NEOPLASM STAGING; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0036898530     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200212000-00010     Document Type: Article

References (24)

1. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease. Am J Clin Pathol 1999; 111:539-43.
2. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-23.
3. Moller MB. P27 in cell cycle control and cancer [In Process Citation]. Leuk Lymphoma 2000;39:19-27.
4. Sgambato A, Cittadini A, Faraglia B, et al. Multiple functions of p27(Kip1) and its alterations in tumor cells: A review. J Cell Physiol 2000;183:18-27.
5. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-7.
6. Yao J, Eu KW, Seow-Choen F, et al. Downregulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas. Int J Cancer 2000;89:213-6.
7. Yokozawa T, Towatari M, Iida H, et al. Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia. Leukemia 2000;14:28-33.
8. Yasui W, Kudo Y, Semba S, et al. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997;88:625-9.
9. Tsuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin- dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 1999;70:230-4.
10. Tannapfel A, Grund D, Katalinic A, et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 2000;89:350-5.
11. Oliveira AM, Nascimento AG, Okuno SH, et al. p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma. J Clin Oncol 2000;18:2888-93.
12. Muller W, Grabsch H, Takeno S, et al. Prognostic value of the cyclin-dependent kinase inhibitor p27Kip1 in gastric cancer. Anticancer Res 2000;20:1787-92.
13. Macri E, Loda M. Role of p27 in prostate carcinogenesis [In Process Citation]. Cancer Metastasis Rev 1998;17:337-44.
14. Kamai T, Takagi K, Asami H, et al. Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int 2000;86:14-9.
15. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
16. Pause A, Lee S, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998;95:993-8.
17. Datta MW, Renshaw AA, Dutta A, et al. Evaluation of cyclin expression in testicular germ cell tumors: Cyclin E correlates with tumor type, advanced clinical stage, and pulmonary metastasis [In Process Citation]. Glycobiology 2000;10:601-9.
18. Corless CL, Kibel AS, Iliopoulos O. et al. Iminunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 1997;28:459-64.
19. Yoshida M, Ashida S, Kondo K, et al. Gerni-line mutation analysis in patients with von Hippel-Lindau disease in Japan: An extended study of 77 families, Jpn J Cancer Res 2000;91:204-12.
20. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997;14:499-506.
21. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;16:5334-44.
22. Sgambato, A. Ratto C. Faraglia B, et al. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog 1999; 26:172-9.
23. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-5.
24. Alessandrini A, Chiaur DS. Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997;11:342-5.